The FDA is considering a change to reduce how often warnings and health disclaimers appear on dietary supplement labels.

The FDA has approved Wegovy (semaglutide) tablets, the first oral GLP-1 receptor agonist for the treatment of obesity.

Spectral speech features may serve as noninvasive biomarkers for monitoring attention and executive function in major depressive disorder.

A set of 6 distinct midlife depressive symptoms appear to be associated with an increased risk for dementia later in life.